153Sm-DOTMP (153Sm-CycloSAM) is a bone pain palliation agent under development by the US company Isotherapeutics. Original patents are dated from 1989. This product must be considered as a generic, was considered as on hold and is now (2020) reactivated and developed by the company QSAM Biosciences, Inc. It localizes to bone surfaces in the same way as 153Sm-EDTMP (Quadramet®)
Target/Mechanism: Bone tissue
Leading Emitter: beta electrons (β–)